Immobilization in stereotactic radiotherapy: the head and neck localizer frame

Dosimetric characteristics of dual-layer multileaf collimation for small-field and intensity-modulated radiation therapy applications

The purpose of the present work was to measure the performance characteristics in the penumbra region and on the leaf‐end of an innovative dual‐layer micro multileaf collimator (DmMLC). The DmMLC consists of two orthogonal (upper and lower) layers of leaves; a standard MLC consists of one layer. The DmMLC provides unique performance characteristics in smoothing dose undulation, reducing leaf‐end transmission, and reducing MLC field dependence of the leaf stepping angle. Two standard MLCs (80‐leaf and 120‐leaf versions: Varian Medical Systems, Palo Alto, CA), a DmMLC (AccuKnife: Initia Medical Technology, Canton, MA), and a Cerrobend (Cerro Metal Products, Bellefonte, PA) block were used in performance studies involving a triangular field, a cross leaf‐end field, and a circular field. Measurements were made with 6‐MV X‐rays and extended dose range film at a depth of 5 cm in Solid Water (Gammex rmi, Middleton, WI) at a source–axis distance of 100 cm. The field penumbra width measured between the 20% and 80% isodose lines through the MLC‐80, MLC‐120, DmMLC, and Cerrobend block were 9.0, 5.0, 3.0, and 2.0 mm respectively. The dose undulation amplitude of the 50% isodose line was measured as 5.5, 2.0, and 0.5 mm for the MLC‐80, MLC‐120, and DmMLC respectively. The planar dose difference between the MLC‐80, MLC‐120, and DmMLC against Cerrobend block was measured as ranging at ±52.5%,±35.0%, and ±20.0% respectively. The leaf‐end transmission was measured at 22.4% in maximum and 15.4% in average when closing a single layer of the DmMLC, and at 2.4% in maximum and 2.1% in average when closing both layers. The MLC dependence of the leaf stepping angle with the DmMLC ranged from 45 degrees to 90 degrees. The standard MLC leaf stepping angle ranged from 0 degrees to 90 degrees. In conclusion, the dose undulation, leaf‐end transmission, and MLC field dependence of the leaf stepping angle with the DmMLC were remarkably reduced as compared with those of the standard MLCs. And as compared with Cerrobend block, the DmMLC provided very comparable performance in field‐edge smoothing and in the shaping of complex fields.

PACS numbers: 87.56.Jk, 87.56.Nk, 87.56.Nj, 87.57.Nt

DVHs evaluation in brain metastases stereotactic radiotherapy treatment plans

PURPOSE

The aim of this work is to report a retrospective study of radiobiological indicators based on Dose-Volume Histograms analysis obtained by stereotactic radiotherapy treatments.

METHODS AND MATERIALS

Fifty-five patients for a total of sixty-seven brain metastases with a mean target volume of 8.49 cc were treated by Dynamic Conformal Arc Therapy (DCAT) and Intensity-Modulated Stereotactic Radiotherapy (IMRST). The Delivered prescription dose was chosen on the basis of tumor size and location so as to ensure a 100% isodose coverage to the target volume.

RESULTS

The treatment plans reported a mean value of 10% and 2.19% for the inhomogeneity and conformal index, respectively. The F factor showed we overdosed sixty-three patients delivering an additional 7% dose more than calculated values. The radiobiological parameters: TCP and NTCP showed a complete tumor control limiting the organs at risk damage.

CONCLUSION

One goal of stereotactic radiotherapy is to design a treatment plan in which the steep dose gradient achievable minimizes the amount of radiation delivered outside the tumor region. This technique allows to deliver a much larger dose to the target without exceeding the radiation-related tolerance of normal tissues and improving patients' quality of life.

Stereotactic body radiation therapy in multiple organ sites

INTRODUCTION

Stereotactic body radiation therapy (SBRT) uses advanced technology to deliver a potent ablative dose to deep-seated tumors in the lung, liver, spine, pancreas, kidney, and prostate.

METHODS

SBRT involves constructing very compact high-dose volumes in and about the tumor. Tumor position must be accurately assessed throughout treatment, especially for tumors that move with respiration. Sophisticated image guidance and related treatment delivery technologies have developed to account for such motion and efficiently deliver high daily dose. All this serves to allow the delivery of ablative dose fractionation to the target capable of both disrupting tumor mitosis and cellular function.

RESULTS

Prospective phase I dose-escalation trials have been carried out to reach potent tumoricidal dose levels capable of eradicating tumors with high likelihood. These studies indicate a clear dose-response relationship for tumor control with escalating dose of SBRT. Prospective phase II studies have been reported from several continents consistently showing very high levels of local tumor control. Although late toxicity requires further careful assessment, acute and subacute toxicities are generally acceptable. Patterns of toxicity, both clinical and radiographic, are distinct from those observed with conventionally fractionated radiotherapy as a result of the unique biologic response to ablative fractionation.

CONCLUSION

Prospective trials using SBRT have confirmed the efficacy of treatment in a variety of patient populations. Although mechanisms of ablative-dose injury remain elusive, ongoing prospective trials offer the hope of finding the ideal application for SBRT in the treatment arsenal.

Patient Set-up in Radiotherapy with Video-based Positioning System

The precision of patient position set-up is important in radiotherapy. A simple and effective scheme is proposed to calibrate the binocular cameras into the treatment machine co-ordinate system to accomplish the patient's first set-up using the video-based positioning system. We also introduce the marking of points on the surface of the body, which can be clearly imaged by computed tomography and are easily recognised from the photograph by the charge coupled device (CCD) camera. By comparing the real-time co-ordinates of the marked points with those obtained from the computed tomography, and with subsequent adjustment, the patient's first set-up in radiotherapy is realised with the video-based positioning system.

Commissioning and quality assurance of a commercial stereotactic treatment-planning system for extracranial IMRT

A 3D treatment‐planning system (TPS) for stereotactic intensity‐modulated radiotherapy (IMRT) using a micro‐multileaf collimator has been made available by Radionics. In this work, we report our comprehensive quality assurance (QA) procedure for commissioning this TPS. First, the accuracy of stereotaxy established with a body frame was checked to ensure accurate determination of a target position within the planning system. Second, the CT‐to‐electron density conversion curve used in the TPS was fitted to our site‐specific measurement data to ensure the accuracy of dose calculation and measurement verification in a QA phantom. Using the QA phantom, the radiological path lengths were verified against known geometrical depths to ensure the accuracy of the ray‐tracing algorithm. We also checked inter‐ and intraleaf leakage/transmission for adequate jaw settings. Measurements for dose verification were performed in various head/neck and prostate IMRT treatment plans using the patient‐specific optimized fluence maps. Both ion chamber and film were used for point dose and isodose distribution verifications. To ensure that adjacent organs at risk receive dose within the expectation, we used the Monte Carlo method to calculate dose distributions and dose‐volume histograms (DVHs) for these organs at risk. The dosimetric accuracy satisfied the published acceptability criteria. The Monte Carlo calculations confirmed the measured dose distributions for target volumes. For organs located on the beam boundary or outside the beam, some differences in the DVHs were noticed. However, the plans calculated by both methods met our clinical criteria. We conclude that the accuracy of the XKnife™ RT2 treatment‐planning system is adequate for the clinical implementation of stereotactic IMRT.

PACS numbers: 87.53.Xd, 87.53.Ly, 87.53.Wz

3D optoelectronic analysis of interfractional patient setup variability in frameless extracranial stereotactic radiotherapy

PURPOSE

To investigate size and frequency of interfractional patient setup variability in hypofractionated stereotactic extracranial radiotherapy.

METHODS AND MATERIALS

Infrared optical 3D tracking of surface markers was applied to quantify setup variability on 51 patients. Isocenter position repeatability was assessed by means of frameless anatomic calibration and was compared with portal image evaluation. Specific data analysis allowed for compensation of patients' breathing movements and for separation of the effects of operator-dependent misalignments and respiration-induced displacements. Effects of patient position (supine vs. prone) and treatment table configuration were investigated.

RESULTS

Patient positioning assisted by the optical tracking device allowed reducing displacements of surface control points within the 3-mm range. Errors in isocenter localization were in the range of a few millimeters. This was in agreement with the portal image evaluation. Breathing motion introduced appreciable errors, which increased control points and isocenter 3D variability. This effect was significantly higher than those related to other investigated factors.

CONCLUSIONS

The role of infrared optical tracking devices for patient positioning is assessed on a large patient population. Their use in the frame of high-precision radiotherapy is emphasized by the application of related methodologies for breathing phase detection and frameless isocenter localization.